v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating activities    
Net earnings $ 6,481 $ 6,474
Noncash items:    
Depreciation and amortization 1,029 1,061
Deferred income taxes 540 64
Share-based compensation 348 375
Loss on sale of subsidiary and subsidiaries held for sale 72 15
Other, net (304) 97
Net change in other operating items, net of effects from acquisitions and dispositions:    
Accounts receivable (3,544) (4,462)
Other assets 2,919 (544)
Medical costs payable 296 2,993
Accounts payable and other liabilities 1,055 (607)
Unearned revenues 20 (10)
Cash flows from operating activities 8,912 5,456
Investing activities    
Purchases of investments (6,515) (4,135)
Sales of investments 1,878 3,185
Maturities of investments 2,285 2,167
Cash paid for acquisitions and other transactions, net of cash assumed 0 (702)
Purchases of property, equipment and capitalized software (763) (898)
Repayments of care provider loans - cyberattack 82 891
Originations And Purchases Of Loans (1,215) (833)
Repayments and maturities of loans 699 254
Cash received from dispositions and other strategic transactions, net 1,081 21
Other, net 21 (24)
Cash flows used for investing activities (2,447) (74)
Financing activities    
Common share repurchases 0 (3,000)
Cash dividends paid (2,005) (1,912)
Proceeds from common stock issuances 231 360
Repayments of long-term debt (1,500) 0
Proceeds from short-term borrowings, net 1,100 3,911
Customer funds administered 600 1,245
Other, net (1,418) (505)
Cash flows (used for) from financing activities (2,992) 99
Effect of exchange rate changes on cash and cash equivalents (7) 15
Increase in cash and cash equivalents, including cash within businesses held for sale 3,466 5,496
Less: net increase in cash within businesses held for sale 170 (91)
Net increase in cash and cash equivalents 3,636 5,405
Cash and cash equivalents, beginning of period 24,365 25,312
Cash and cash equivalents, end of period $ 28,001 $ 30,717